Streptomycin sulphate loaded solid lipid nanoparticles show enhanced uptake in macrophage, lower MIC in Mycobacterium and improved oral bioavailability

Singh, Mandeep; Schiavone, Nicola; Papucci, Laura; Maan, Prathiba; Kaur, Jagdeep; Singh, Gurdarshan; Nandi, Utpal; Nosi, Daniele; Tani, Akio; Khuller, G. K.; Priya, M. R. Kamala; Singh, Ramandeep; Kaur, Indu Pal

doi:10.1016/j.ejpb.2021.01.009

Cited by 19 publications

(6 citation statements)

References 99 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LNPs containing streptomycin sulphate (STRS) were prepared using a cold high-pressure homogenization method, and achieved 30% DL and 51.17 AE 0.95% EE. [136] The synthesized STRS-loaded LNPs were able to overcome the gastric barriers with a significant intracellular uptake increase and a controlled release. Furthermore, an enhanced bioavailability (1.6-7 times higher) was achieved in in vivo studies when comparing to free drugs.…”

Section: Water-soluble Drugsmentioning

confidence: 98%

Lipid Nanoparticles for Drug Delivery

Wang

Liu

et al. 2021

Advanced NanoBiomed Research

243

110

View full text Add to dashboard Cite

Lipid nanoparticles have attracted significant interests in the last two decades, and have achieved tremendous clinical success since the first clinical approval of Doxil in 1995. At the same time, lipid nanoparticles have also demonstrated enormous potential in delivering nucleic acid drugs as evidenced by the approval of two RNA therapies and mRNA COVID‐19 vaccines. In this review, an overview on different classes of lipid nanoparticles, including liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, is first provided, followed by the introduction of their preparation methods. Then the characterizations of lipid nanoparticles are briefly reviewed and their applications in encapsulating and delivering hydrophobic drugs, hydrophilic drugs, and RNAs are highlighted. Finally, various applications of lipid nanoparticles for overcoming different delivery challenges, including crossing the blood–brain barrier, targeted delivery, and various routes of administration, are summarized. Lipid nanoparticles as drug delivery systems offer many attractive benefits such as great biocompatibility, ease of preparation, feasibility of scale‐up, nontoxicity, and targeted delivery, while current challenges in drug delivery warrant future studies about structure–function correlations, large‐scale production, and targeted delivery to realize the full potential of lipid nanoparticles for wider clinical and pharmaceutical applications in future.

show abstract

Section: Water-soluble Drugsmentioning

confidence: 98%

Lipid Nanoparticles for Drug Delivery

Wang

Liu

et al. 2021

Advanced NanoBiomed Research

243

110

View full text Add to dashboard Cite

show abstract

“…The acute cytotoxicity studies indicated the safety of developed formulation both in vitro and in vivo. Finally, a pharmacokinetics study of developed formulation in rats showed a significant increase (160-710%) in oral absorption and bioavailability compared to pure STRS (Singh et al, 2021).…”

Section: Solid Lipid Nanoparticlesmentioning

confidence: 94%

Nanocarrier-Based Approaches for the Efficient Delivery of Anti-Tubercular Drugs and Vaccines for Management of Tuberculosis

2021

View full text Add to dashboard Cite

Drug-resistant species of tuberculosis (TB), which spread faster than traditiona TB, is a severely infectious disease. The conventional drug therapy used in the management of tuberculosis has several challenges linked with adverse effects. Hence, nanotherapeutics served as an emerging technique to overcome problems associated with current treatment. Nanotherapeutics helps to overcome toxicity and poor solubility issues of several drugs used in the management of tuberculosis. Due to their diameter and surface chemistry, nanocarriers encapsulated with antimicrobial drugs are readily taken up by macrophages. Macrophages play a crucial role as they serve as target sites for active and passive targeting for nanocarriers. The surface of the nanocarriers is coated with ligand-specific receptors, which further enhances drug concentration locally and indicates the therapeutic potential of nanocarriers. This review highlights tuberculosis’s current facts, figures, challenges associated with conventional treatment, different nanocarrier-based systems, and its application in vaccine development.

show abstract

“…This indicated that SLNs loaded with enrofloxacin had a far better inhibitory effect on intracellular Salmonella than free enrofloxacin, and 0.6 μg mL −1 SLNs with enrofloxacin could reduce the number of intracellular bacteria by 99.97%. Furthermore, Singh et al 12 successfully prepared oral streptomycin-loaded SLNs (STRS-SLNs) using a cold, high-pressure homogenisation technique. The cellular uptake rate of STRS-SLNs was 60 times higher than that of free streptomycin, and the MIC for intracellular M. tb H37RV (256182) was reduced by 3 times.…”

Section: Liposomesmentioning

confidence: 99%

“…In recent years, the effective delivery of antibiotics into cells based on nanotechnology for the enhancement of intracellular antibacterial activity has become a hot spot in anti-intracellular bacterial infection research. [12][13][14] Although there are many reviews of nanocarriers, most of the nanocarriers are used to deliver anti-tumor drugs, 15 genes 16 or CRISPR gene editing systems. 17 And those reported nanocarriers used to deliver antibiotics mainly focused on local delivery to improve drug concentration at the infection site 18 and overcoming bacterial envelope barrier to promote bacterial internalization of antibiotic.…”

Section: Introductionmentioning

confidence: 99%